
Kia Carens Clavis EV launched with 490 km range, prices start at ₹17.99 lakh
Kia has launched its first mass-market electric offering in India in the form of the new Carens Clavis EV. The new Kia Carens Clavis EV is priced from ₹ 17.99 lakh and goes up to ₹ 24.49 lakh (ex-showroom). The new offering is based on the localised E-GMP platform and shares its underpinnings with the recently launched facelifted Carens Clavis. Kia says its new electric people mover promises the same comfort and premium cabin experience, while ensuring zero tailpipe emissions. Bookings open on July 22, 2025.
Kia Carens Clavis EV: Power & Range
Powering the Carens Clavis EV is a single motor tuned to develop 169 bhp and 255 Nm of peak torque. 0-100 kmph comes up in 8.4 seconds, while power comes from the 51.4 kWh battery pack that promises 490 km of claimed range on a single charge. A smaller 42 kWh battery pack offers a range of 404 km (ARAI) on full charge.
Also Read : Kia Carens Clavis EV launched in India: Check range, features, bookings & more The Kia Carens Clavis EV looks identical to the ICE-powered model, but gets new 17-inch aero diamond-cut alloy wheels that give it a different look Kia Carens Clavis EV: Revised Design
The design language is identical to the ICE Carens Clavis but with electric-specific changes. The charging point is now part of the closed grille, while the LED DRLs run across the width of the front profile. The rest of the design is likely to remain identical, ensuring maximum room in the cabin. The model gets new 17-inch aero alloy wheels that give the electric Carens Clavis a different appearance. The model also comes with an underbody cover, but the ground clearance is 5 mm more than its ICE sibling, at 200 mm. The cabin is identical to the ICE Carens Clavis, but the gear shifter has moved to the steering column, from the centre console Kia Carens Clavis EV: Interior
The Kia Carens Clavis EV is the most accessible three-row electric offering to go on sale in India. Kia has liberated more space by moving the gear shifter to the steering column, instead of a conventional shifter. The electric MPV comes with a 26.6-inch panoramic display comprising two screens for the digital console and infotainment system. The model comes with over 90 connected features, while also carrying over features like Level 2 ADAS, wireless charging, a panoramic sunroof, ambient lighting, a one-touch tumble-down second row seat, ventilated front seats, an electrically adjustable driver's seat, ambient lighting, an air purifier, and more.
Also Read : Kia Carens Clavis First Drive Review - New mask, same task Bookings for the new Kia Carens Clavis EV open on July 22, 2025
The model gets a 25-litre frunk, in addition to the traditional cargo space behind the third row. The Carens Clavis EV supports 7.4 kW and 11 kW AC chargers. Kia says over 100 of its dealerships are equipped with fast chargers, while the automaker has over 11,000 charging stations as it builds its infrastructure. The automaker is offering 8 years/160,000 km warranty on the electric MPV. Kia Carens Clavis EV: Rivals
The Carens Clavis EV does not have a direct rival but takes on the Tata Curvv EV, Hyundai Creta Electric, MG ZS EV, Tata Harrier EV, and more.
Check out Upcoming EV Cars in India.
First Published Date: 15 Jul 2025, 12:37 pm IST

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


News18
2 hours ago
- News18
Dr Reddys gets seven observations from USFDA for Andhra plant
New Delhi, Jul 20 (PTI) Dr Reddy's Laboratories has received a Form 483 with seven observations from the US health regulator for its Srikakulam-based plant in Andhra Pradesh, according to a regulatory filing. The US Food and Drug Administration (USFDA) conducted the GMP and a Pre-Approval Inspection (PAI) at the formulations manufacturing facility from July 10 to 18, 2025, the Hyderabad-based drug major said in the filing. 'We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," it added. As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related Acts. PTI MSS BAL BAL Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.


Time of India
3 hours ago
- Time of India
Dr Reddy's gets seven observations from USFDA for Andhra plant
Dr Reddy's Laboratories has received a Form 483 with seven observations from the US health regulator for its Srikakulam-based plant in Andhra Pradesh , according to a regulatory filing. The US Food and Drug Administration ( USFDA ) conducted the GMP and a Pre-Approval Inspection (PAI) at the formulations manufacturing facility from July 10 to 18, 2025, the Hyderabad-based drug major said in the filing. Explore courses from Top Institutes in Select a Course Category Management healthcare Degree Leadership Project Management Others Data Science Design Thinking CXO Cybersecurity Data Science MCA PGDM MBA Operations Management Data Analytics Digital Marketing Product Management others Public Policy Technology Healthcare Finance Artificial Intelligence Skills you'll gain: Duration: 11 Months IIM Kozhikode CERT-IIMK General Management Programme India Starts on undefined Get Details Skills you'll gain: Duration: 9 Months IIM Calcutta CERT-IIMC APSPM India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK GMPBE India Starts on undefined Get Details "We have been issued a Form 483 with seven observations, which we will address within the stipulated timeline," it added. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 15 Most Beautiful Female Athletes in the World Click Here Undo As per the USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food, Drug and Cosmetic (FD&C) Act and related Acts.


Time of India
4 hours ago
- Time of India
'Urban River Management Plan' launched to clean Yamuna in Delhi
An Urban River Management Plan , or URMP, has been launched to clean and rejuvenate the Yamuna River in the national capital. The plan is an initiative of the National Mission for Clean Ganga , launched in collaboration with the National Institute of Urban Affairs and the Delhi government. Explore courses from Top Institutes in Select a Course Category Data Science Management Degree Cybersecurity MCA Operations Management Design Thinking Product Management MBA Leadership Digital Marketing Project Management Data Science Data Analytics Others CXO Technology Healthcare Artificial Intelligence Public Policy healthcare PGDM others Finance Skills you'll gain: Duration: 10 Months IIM Kozhikode CERT-IIMK DABS India Starts on undefined Get Details Skills you'll gain: Duration: 30 Weeks IIM Kozhikode SEPO - IIMK-AI for Senior Executives India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months IIT Madras CERT-IITM Advanced Cert Prog in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 11 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Postgraduate Cert in AI and ML India Starts on undefined Get Details Skills you'll gain: Duration: 10 Months E&ICT Academy, Indian Institute of Technology Guwahati CERT-IITG Prof Cert in DS & BA with GenAI India Starts on undefined Get Details The NMCG Director General Rajeev Kumar Mital stressed that the URMP must function as a live document, not just a policy report. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas Prices In Dubai Might Be More Affordable Than You Think Villas In Dubai | Search Ads Get Quote Undo "It should guide action through scientific understanding, risk-based assessments and strong participation from all stakeholders ," he said.